This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
-
Patient Perspectives on AI-Drafted Electronic Portal Messages
Kellie Owens, et al.. JAMA Network Open, 2026.
DOI: 10.1001/jamanetworkopen.2026.22463
-
Statement on the Launch of the Bio Genesis Mission, NIH’s component of the national Genesis Mission
Weekly News Brief: July 27–31, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of July 27–31, 2026.
This week’s brief covers the FDA approval of a new AI-enabled blood test for colorectal cancer screening, patient attitudes toward AI-drafted physician portal messages, and the NIH's Bio Genesis Mission to accelerate AI-driven biomedical discovery.
To learn more about SimpleScreen CRC, read "SimpleScreen CRC Approved by FDA to Test for Colorectal Cancer," or see the press release.
For more information on patient preferences on AI-drafted messages, read "Patients Back AI-Drafted Portal Messages," or see the source report in JAMA Network Open.
To learn more about the Bio Genesis Mission, read "NIH Launches Bio Genesis Mission to Accelerate AI-Driven Biomedical Discovery," or see the statement.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.